Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This clinical study is a multiple center, registering and real-world conditional research.
The breast cancer patients planning for chemotherapy evaluated with medium-high risk of
febrile neutropenia (FN) are recruited, receiving the first level prophylactic use of
PEG-rhG-CSF or the second level prophylactic use of PEG-rhG-CSF in at least two cycles of
chemotherapy according to real-world clinical judgement and choice by physicians in local
cancer center. Comparing real conditional-FN rate, FN-caused hospitalization rate and
antibiotic use rate, direct/indirect medical cost.